.jpg?format=webp&width=780)
The prevalence of metabolic syndrome (MS), which mainly includes hypertension, hyperglycemia, and hyperlipidemia, remains high, and the safety and antibody response of inactivated coronavirus disease 2019 (COVID-19) vaccination in patients with metabolic syndrome (MS) is still inconsistency; therefore it is necessary to explore the safety and antibody responses of inactivated COVID-19 vaccination in MS patients in clinical practice. In this study, 157 adults patients who were suffering from MS and 117 health controls (HC) at an interval of at least 21 days after full-course (2nd dose) vaccination were enrolled. The study results showed that inactivated COVID-19 vaccines were well-tolerated but induced a poorer antibody response against SARS-CoV-2 in MS patients compared to HC participants. Patients with MS should therefore be more proactive in receiving inactivated COVID-19 vaccine, and a booster vaccination may be considered necessary.
Like
Save
Share